Abstract
The post-transcriptional modification of tRNAs plays a key role in tRNA folding and function to ensure proper levels of protein synthesis during growth and development. Pathogenic variants in tRNA modification enzymes have been implicated in diverse human neurodevelopmental and neurological disorders. However, the molecular basis for many of these disorders remains unknown, thereby limiting our understanding and potential treatment of pathologies linked to tRNA modification. Here, we describe an extensive cohort of 31 individuals from 24 unrelated families with bi-allelic variants in the tRNA methyltransferase 1 (TRMT1) gene who present with a syndromic neurodevelopmental disorder universally characterized by intellectual disability in affected patients. Developmental delay, behavioral abnormalities and facial dysmorphisms represent additional core phenotypes of this syndrome. The variants include novel and ultra-rare TRMT1 variants that segregate with clinical pathology. We found that a subset of variants causes mis-splicing and loss of TRMT1 protein expression. Notably, patient cells with TRMT1 variants exhibit a deficiency in tRNA modifications catalyzed by TRMT1. Molecular analysis of TRMT1 variants reveal distinct regions of the TRMT1 protein required for tRNA modification activity and binding, including a TRMT1 subdomain critical for tRNA interaction. Importantly, depletion of TRMT1 in zebrafish is sufficient to induce developmental and behavioral phenotypes that recapitulate those observed in human patients with pathogenic TRMT1 variants. Altogether, these findings demonstrate that loss of TRMT1-catalyzed tRNA modifications leads to a syndromic form of intellectual disability and elucidate the molecular underpinnings of tRNA modification deficiency caused by pathogenic TRMT1 variants.
Competing Interest Statement
M.M.M and A.C are employees of GeneDx, LLC. R.S. is on the advisory board for Guide Genetics and Egetis Pharmaceuticals.
Funding Statement
The research in this manuscript was supported by NIH GR530882 to D.F. Studies performed in the lab of G.K.V was funded by NIH R24OD034438. The clinic-genetic research was funded in part, by the Wellcome Trust (WT093205MA, WT104033AIA). This study was funded by the Medical Research Council (MR/S01165X/1, MR/S005021/1, G0601943), The National Institute for Health Research University College London Hospitals Biomedical Research Centre, Rosetrees Trust, Ataxia UK, Multiple System Atrophy Trust, Brain Research United Kingdom, Sparks Great Ormond Street Hospital Charity, Muscular Dystrophy United Kingdom (MDUK), Muscular Dystrophy Association (MDA USA) and the King Baudouin Foundation. SE and HH were supported by an MRC strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1. B.V. was supported by the Deutsche Forschungsgemeinschaft (DFG) DFG VO 2138/7‐1 grant 469177153. J.S. is supported by Cancer Research UK and University College London. A.F. and S.C. are supported by Health & Care Research Wales, Epilepsy Research UK, PhD Swansea University funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The accredited Medical Ethics Review Committee of the University College London Hospital, as well as all collaborating local institutional IRBs have approved the collection of biomaterial samples and clinical information as well as functional analysis of human DNA and fibroblasts. The patients and their families provided informed consent for participation in the study and publication of the results.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The data that supports the findings of this study are available within the paper and in the supplementary material. Whole-exome sequencing data are not publicly available due to privacy or ethical restrictions. The novel TRMT1 variants reported in this manuscript were submitted to the LOVD database (https://databases.lovd.nl/shared/genes/TRMT1), with the LOVD variant IDs: # 0000944528, # 0000944622, # 0000944624, # 0000944625, # 0000944626, # 0000944640, # 0000944641, # 0000944642, # 0000944643, # 0000944646, # 0000944620, # 0000944621, # 0000944647, # 0000944709, # 0000944708, # 0000944710, # 0000944712, # 0000944713, # 0000944714, # 0000944715, # 0000944716, #0000959740, #0000959741, #0000959742, #0000959743.
